Ixempra
Payments companies reported to CMS as associated with Ixempra. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Ixempra, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Ixempra
These are the largest totals companies reported as associated with Ixempra. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Alexander Olawaiye | Pittsburgh, PA | Gynecologic Oncology | $433.72 |
| Alessandro Santin | New Haven, CT | Obstetrics & Gynecology | $229.93 |
| Pedro Gil Solivan Ortiz | Rio Piedras, PR | $151.60 | |
| Nuhad Ibrahim | Houston, TX | Medical Oncology | $83.52 |
| Mark Shahin | Hershey, PA | Gynecologic Oncology | $59.48 |
| Adam Brufsky | Pittsburgh, PA | $51.18 | |
| Rachel Layman | Houston, TX | Medical Oncology | $41.78 |
| Mario Leitao | New York, NY | Gynecologic Oncology | $32.00 |
| Stephen Graves | Columbus, OH | Obstetrics & Gynecology | $32.00 |
| Anna Curtin | Boise, ID | Obstetrics & Gynecology | $32.00 |
Prescribed Ixempra?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.